Not A Biosimilar: Mylan’s Insulin Glargine ‘Deemed’ A BLA With Long-Awaited US FDA Approval

 
• By Sue Sutter
  
the happiness of the person reaching the goal after a determined and patient struggle
After two complete response letters, Mylan and Biocon finally scored US FDA approval of their insulin glargine. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics